Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
NCT07315113
This study is recruiting at 5 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- EGFR Mutation Positive Non-small Cell Lung Cancer
- EGFR Mutated Non-small Cell Lung Cancer Patients
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Nuvectis Pharma, Inc.
- Last updated on ClinicalTrials.gov
- July 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Maryland Oncology Hematology · Calverton, MD
Oregon · 1
- Willamette Valley Cancer Institute and Research Center · Eugene, OR
Pennsylvania · 1
- UPMC Hillman Cancer Center · Pittsburgh, PA
Texas · 1
- NEXT Houston · Houston, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.